Tags

Type your tag names separated by a space and hit enter

Overview of the 3rd isirv-Antiviral Group Conference--advances in clinical management.
Influenza Other Respir Viruses. 2015 Jan; 9(1):20-31.IO

Abstract

This review highlights the main points which emerged from the presentations and discussions at the 3rd isirv-Antiviral Group Conference - advances in clinical management. The conference covered emerging and potentially pandemic influenza viruses and discussed novel/pre-licensure therapeutics and currently approved antivirals and vaccines for the control of influenza. Current data on approved and novel treatments for non-influenza respiratory viruses such as MERS-CoV, respiratory syncytial virus (RSV) and rhinoviruses and the challenges of treating immunocompromised patients with respiratory infections was highlighted.

Authors+Show Affiliations

WHO Collaborating Centre for Reference and Research on Influenza, VIDRL at the Peter Doherty Institute for Infection and Immunity, Parkville, Vic., Australia; Melbourne School of Population and Global Health, University of Melbourne, Parkville, Vic., Australia.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

25399715

Citation

Hurt, Aeron C., et al. "Overview of the 3rd isirv-Antiviral Group Conference--advances in Clinical Management." Influenza and Other Respiratory Viruses, vol. 9, no. 1, 2015, pp. 20-31.
Hurt AC, Hui DS, Hay A, et al. Overview of the 3rd isirv-Antiviral Group Conference--advances in clinical management. Influenza Other Respir Viruses. 2015;9(1):20-31.
Hurt, A. C., Hui, D. S., Hay, A., & Hayden, F. G. (2015). Overview of the 3rd isirv-Antiviral Group Conference--advances in clinical management. Influenza and Other Respiratory Viruses, 9(1), 20-31. https://doi.org/10.1111/irv.12293
Hurt AC, et al. Overview of the 3rd isirv-Antiviral Group Conference--advances in Clinical Management. Influenza Other Respir Viruses. 2015;9(1):20-31. PubMed PMID: 25399715.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Overview of the 3rd isirv-Antiviral Group Conference--advances in clinical management. AU - Hurt,Aeron C, AU - Hui,David S, AU - Hay,Alan, AU - Hayden,Frederick G, Y1 - 2014/11/15/ PY - 2014/10/14/accepted PY - 2014/11/18/entrez PY - 2014/11/18/pubmed PY - 2015/8/5/medline KW - Antivirals KW - clinical management KW - immunocompromised KW - influenza KW - respiratory KW - treatment SP - 20 EP - 31 JF - Influenza and other respiratory viruses JO - Influenza Other Respir Viruses VL - 9 IS - 1 N2 - This review highlights the main points which emerged from the presentations and discussions at the 3rd isirv-Antiviral Group Conference - advances in clinical management. The conference covered emerging and potentially pandemic influenza viruses and discussed novel/pre-licensure therapeutics and currently approved antivirals and vaccines for the control of influenza. Current data on approved and novel treatments for non-influenza respiratory viruses such as MERS-CoV, respiratory syncytial virus (RSV) and rhinoviruses and the challenges of treating immunocompromised patients with respiratory infections was highlighted. SN - 1750-2659 UR - https://www.unboundmedicine.com/medline/citation/25399715/Overview_of_the_3rd_isirv_Antiviral_Group_Conference__advances_in_clinical_management_ L2 - https://doi.org/10.1111/irv.12293 DB - PRIME DP - Unbound Medicine ER -